Washington, D.C.’s medical marijuana program reported $10,939,371 in total sales for September 2025, a sharp 182% increase over the $3,884,222 recorded in September 2024, and well above the previous monthly record of $8.8 million.
According to the Alcoholic Beverage and Cannabis Administration, manufacturers accounted for the majority of growth, with sales surging to $5.18 million in September. Dispensaries also performed strongly, generating $5.2 million, up from $2.58 million in September 2024. Cultivation centers, however, declined slightly year-over-year, dropping from $618,729 to $528,178.
Patient participation continued to expand. The report shows over 78,700 unique patients registered in September, up from 73,407 in August. More than 31,000 patients purchased from licensed dispensaries, including 18,497 D.C. residents, 2,128 reciprocity patients, and 10,664 temporary self-certified patients.
Dried flower remained the top-selling product category, with 572 pounds sold for more than $2.8 million. Vape cartridges followed, totaling nearly $986,000 across 19,453 units. Raw pre-rolls continued to grow in popularity, generating over $526,000, while infused pre-rolls more than doubled month-to-month, reaching $48,000. Edibles, tinctures, and topicals all saw moderate sales, though most categories dipped slightly from August.
Non-resident activity remained steady. Maryland led reciprocity participation with 848 patients, followed by Virginia with 802 and Florida with 116. For temporary registrations, Virginia again dominated with 3,360, trailed by Maryland (1,385) and North Carolina (682).
Enforcement efforts intensified in September. Inspectors closed eight unlicensed facilities, marking the highest number of closures so far this year, though no cannabis waste was destroyed during the month. The agency also conducted eight scheduled inspections.
